Sort
40,608 grants matching “prostate cancer”
Precisely Shaped Acoustic Ablation of Tumors Under 3D Ultrasound Image Guidance
$1,000,000Everette C Burdette · Acoustic Medsystems, Inc. · R44 · FY2010 · CA
Commercializing Praedicare Dx TM platform for guiding cancer treatments
$1,000,000Michael H Cardone · Eutropics Pharmaceuticals, Inc. · R44 · FY2019 · CA
MicroRNA-based Radiation Biodosimeter (MiRAD) Phase II
$1,000,000Claude J. Rogers · Chromologic, Llc · R44 · FY2019 · AI
Leveraging Prospective Cancer Epidemiology Cohorts and Novel Methods to Improve Polygenic Risk Scores
$1,000,000Fei Chen · University Of Southern California · U01 · FY2025 · CA
Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients
$999,999Theresa Deisher · Avm Biotechnology, Llc · R44 · FY2022 · CA
Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients
$999,999Theresa Deisher · Avm Biotechnology, Llc · R44 · FY2023 · CA
Spectroscopic Localization of Breast Cancer
$999,999David A. Benaron · Spectros Corporation · R44 · FY2008 · CA
Development of a Commercial-Ready Kit for CTT1403, a Novel PSMA-Targeted Radiotherapy
$999,998Hunter Nicole Bomba · Cancer Targeted Technology, Llc · R44 · FY2022 · CA
Thyroid Cancer Aggressiveness in WTC Responders
$999,987Emanuela Taioli · Icahn School Of Medicine At Mount Sinai · U01 · FY2020 · OH
DP21-003 Scaling Social Determinants of Health Screening, Social Support and Anti-Racism Training to Reduce Inequities in Minority Cancer Survivor Health and Wellbeing in Washington, DC
$999,967Hannah Arem · Medstar Health Research Institute · U01 · FY2025 · DP
Targeting Tumor-Derived exRNA-Containing Microvesicles by High Throughput Screeni
$999,920Asim B Abdel-Mageed · Tulane University Of Louisiana · UH3 · FY2016 · TR
Targeting Tumor-Derived exRNA-Containing Microvesicles by High Throughput Screeni
$999,911Asim B Abdel-Mageed · Tulane University Of Louisiana · UH3 · FY2017 · TR
MicroRNA-based Radiation Biodosimeter (MiRAD) Phase II
$999,895Claude J. Rogers · Chromologic, Llc · R44 · FY2020 · AI
MicroRNA-based Radiation Biodosimeter (MiRAD) Phase II
$999,884Claude J. Rogers · Chromologic, Llc · R44 · FY2018 · AI
Howard/Hopkins Cancer Centers Partnership
$999,884Martin D Abeloff · Johns Hopkins University · U54 · FY2006 · CA
Plant-based diets and risk of cancer
$999,864Gary E. Fraser · Loma Linda University · U01 · FY2012 · CA
Thyroid Cancer Aggressiveness in WTC Responders
$999,774Emanuela Taioli · Icahn School Of Medicine At Mount Sinai · U01 · FY2019 · OH
Leveraging Diversity in Cancer Epidemiology Cohorts and Novel Methods to Improve Polygenic Risk Scores
$999,722David V Conti · University Of Southern California · U01 · FY2021 · CA
DEVELOPMENT OF A NOVEL VASCULAR DISRUPTING AGENT FOR ADVANCED PROSTATE CANCER
$999,699Synta Pharmaceuticals Corp. · · FY2011 · Department of the Army
Commercialization of an MRI contrast agent for differential diagnosis of prostate cancer.
$999,657Yajuan Li · Molecular Theranostics, Llc · R44 · FY2018 · CA
SBIR Topic 241 Phase II: Platelet-based Nanoparticle Therapy for Prostate Cancer
$999,642Michael Zwick · Androbiosys, Inc. · N44 · FY2010 · CA
Avanzando Caminos (Leading Pathways): The Hispanic/Latino Cancer Survivorship Cohort Study.â
$999,612Frank J Penedo · University Of Miami Coral Gables · UG3 · FY2021 · CA
OTHER FUNCTIONS SBIR PHASE II TOPIC 290 "RNAI SYNTHETIC LETHAL SCREEN IN CANCER
$999,596Alexandr Chenchik · Cellecta, Inc. · N44 · FY2012 · CA
HBCU-RISE: Enhancement of Research Infrastructure for the Development of Nanoelectromechanical Systems (NEMS) Devices and Materials
$998,968Hargsoon Yoon · Norfolk State University · · FY2014 · EDU
OTHER FUNCTIONS "DEVELOPMENT OF A UNI-DIRECTIONAL BRACHYTHERAPY DEVICE FOR THE T
$998,964Kristy Perez · Civatech Oncology, Inc. · N44 · FY2012 · CA